Ticker brief
SMMT SUMMIT THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$13.73
1 day
-4.2%
14 days
+2.8%
mkt cap
$12.0B
signals 14d
33
authors 14d
24
crowd 14d
+1.4σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 87% mid · 24 pctile own 1y | IV/HV 1.14× (as of 2026-07-24) |
| Skew — 25Δ RR 30d | +0.093 93 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.24 elevated | 5-session Δ +0.29 (as of 2026-07-07) |
| OI alarm | quiet | last alarm 2026-06-16 (z=2.1) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-28 · now +0.52 (−1 bearish … +1 bullish)
Who spoke24
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 4 | +0.36 |
| @bioinvestor24 | A | -0.45 | 3 | -0.47 |
| @Corgi4joy | C | -0.11 | 3 | +0.55 |
| @SuperDuperInvst | C | -0.99 | 2 | -0.57 |
| @Briefingcom | B | +0.50 | 2 | +0.45 |
| @Financhle | C | · | 1 | -0.70 |
| @fundmyfund | B | -1.58 | 1 | -0.40 |
| @itsmichaelluu | C | -1.92 | 1 | +0.35 |
| @HejToJeMara | B | -1.43 | 1 | -0.50 |
| @BlueJay87476298 | B | -0.02 | 1 | +0.55 |
| @DeItaone | B | -0.84 | 1 | +0.25 |
| @EmmanuelInvest | C | -1.11 | 1 | +0.40 |
| @OzmosiHealth | C | · | 1 | +0.20 |
| @AlertsAndNews | C | -1.90 | 1 | +0.55 |
| @MartyChargin | C | -0.27 | 1 | +0.50 |
| @BankTheTrade | C | +1.63 | 1 | +0.50 |
| @BPharmCatalyst | C | · | 1 | +0.55 |
| @MarketMaestro1 | C | -2.46 | 1 | +0.45 |
| @fwpharma | B | +0.98 | 1 | +0.50 |
| @HedgeFundTips | B | +0.49 | 1 | +0.15 |
| @ACapitalLP | A | +0.05 | 1 | +0.65 |
| @Ben1148x2 | C | +1.01 | 1 | +0.65 |
| @Mr_Derivatives | C | -2.57 | 1 | +0.30 |
| @BiotechCH | B | -0.38 | 1 | +0.65 |
Recent signals30of 33 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @BiopharmIQ | +0.40 | Summarizes major weekly biotech gainers and BTAI's bankruptcy-driven 75% decline | — | tweet ↗ |
| 2026-08-28 | @BiotechCH | +0.65 | Ivonescimab won China approval and delivered a Phase 3 biliary-cancer result. | — | tweet ↗ |
| 2026-08-27 | @Mr_Derivatives | +0.30 | Playfully hopes SMMT eventually makes an MRNA-like move. | -4.2% | tweet ↗ |
| 2026-08-26 | @Ben1148x2 | +0.65 | Play SMMT tomorrow as a short-time-frame fast mover. — Explicitly states intent to trade SMMT the next day. | -3.5% | tweet ↗ |
| 2026-08-26 | @ACapitalLP | +0.65 | The author presents three bullish near-term catalyst ideas with event dates, prices and valuation upside. | -3.5% | tweet ↗ |
| 2026-08-26 | @Corgi4joy | +0.80 | Buy fear-driven weakness in NVDA, QQQ and SMMT. — Explicit forward buy instruction across three named assets. | -3.5% | tweet ↗ |
| 2026-08-26 | @BiopharmIQ | +0.55 | HARMONi-GI1 met OS, PFS, and ORR endpoints, with SMMT shares up 7%. | -3.5% | tweet ↗ |
| 2026-08-26 | @BiopharmIQ | +0.30 | Lists biotech opening moves and associated catalysts across multiple names. | -3.5% | tweet ↗ |
| 2026-08-26 | @HedgeFundTips | +0.15 | Presents a broad list of stocks receiving money flows today. | -3.5% | tweet ↗ |
| 2026-08-26 | @fwpharma | +0.50 | Reports a pivotal Chinese biliary-cancer study win for ivonescimab. | -3.5% | tweet ↗ |
| 2026-08-26 | @MarketMaestro1 | +0.45 | Reports a completed neckline retest and an emerging positive divergence in SMMT. | -3.5% | tweet ↗ |
| 2026-08-26 | @Corgi4joy | +0.70 | Reports SMMT already up 25% and references a three-day holding period. | -3.5% | tweet ↗ |
| 2026-08-26 | @BPharmCatalyst | +0.55 | Partner's Phase 3 trial met OS, PFS, and ORR endpoints in advanced biliary cancer. | -3.5% | tweet ↗ |
| 2026-08-26 | @BankTheTrade | +0.50 | Reports positive phase 3 ivonescimab combination-trial results from partner Akeso. | -3.5% | tweet ↗ |
| 2026-08-26 | @Briefingcom | +0.60 | SMMT partner Akeso reported a Phase III overall-survival win for ivonescimab. | -3.5% | tweet ↗ |
| 2026-08-26 | @Briefingcom | +0.30 | Reports the largest named premarket gaps, capped at six tickers. | -3.5% | tweet ↗ |
| 2026-08-26 | @MartyChargin | +0.50 | Summit partner Akeso reports a Phase III overall-survival win for ivonescimab. | -3.5% | tweet ↗ |
| 2026-08-25 | @AlertsAndNews | +0.55 | Ivonescimab combination achieved significant survival superiority in a China trial. | +2.8% | tweet ↗ |
| 2026-08-25 | @BiopharmIQ | +0.20 | Biotech news roundup lists movers and catalysts; first six explicit tickers retained. | +2.8% | tweet ↗ |
| 2026-08-25 | @OzmosiHealth | +0.20 | Reports publication of global Phase III primary-analysis results in The Lancet Oncology. | +2.8% | tweet ↗ |
| 2026-08-25 | @EmmanuelInvest | +0.40 | Bernstein upgraded Summit to Market Perform and raised its target. | +2.8% | tweet ↗ |
| 2026-08-25 | @DeItaone | +0.25 | Multiple sell-side firms announced upgrades and price-target changes. | +2.8% | tweet ↗ |
| 2026-08-23 | @BlueJay87476298 | +0.55 | Bullish commercial thesis for Summit's ivonescimab as a potential challenger to Merck's Keytruda franchise. | +4.3% | tweet ↗ |
| 2026-08-22 | @Corgi4joy | +0.15 | Flags SMMT near $12.50 as heavily shorted by Jane Street. | +4.3% | tweet ↗ |
| 2026-08-20 | @SuperDuperInvst | -0.70 | Warns SMMT is overvalued while preferring VNDA on fundamentals and valuation. | +10.5% | tweet ↗ |
| 2026-08-20 | @SuperDuperInvst | -0.45 | Calls AMLX very overvalued and predicts heavy eventual selling after the rally. | +10.5% | tweet ↗ |
| 2026-08-20 | @bioinvestor24 | -0.65 | Calls Moderna's positive interim oncology data a platform breakthrough while dismissing SMMT and ABVX approaches. | +10.5% | tweet ↗ |
| 2026-08-20 | @HejToJeMara | -0.50 | Author harshly criticizes five biotechs, emphasizing IMUX's 12.5x share-count dilution. | +10.5% | tweet ↗ |
| 2026-08-19 | @itsmichaelluu | +0.35 | Maps five high-risk biotechnology catalysts after MRNA's Phase 3 success and stresses coin-flip risk. | +4.7% | tweet ↗ |
| 2026-08-19 | @fundmyfund | -0.40 | Lists five names among the next 20 worst weekly performers in a screened universe. | +4.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.